New ACP Breast Cancer Screening Guidelines Are a Step Backward that May Cost Lives
April 18 (BNP): The American College of Radiology (ACR) and the Society of Breast Imaging (SBI) have expressed serious concerns regarding the recent breast cancer screening guidelines issued by the American College of Physicians (ACP), stating that the recommendations rely on outdated and exaggerated information that could lead to confusion among women and potentially increase breast cancer-related deaths.
According to ACR and SBI, delaying screening or reducing its frequency as suggested by ACP may result in up to 10,000 additional breast cancer deaths annually in the United States. The organizations emphasize that early detection through annual screening significantly reduces mortality and the need for aggressive treatments such as mastectomies and chemotherapy.
Both ACR and SBI strongly recommend that women begin annual breast cancer screening at age 40. Additionally, they advise that women undergo a breast cancer risk assessment by age 25 to identify those at higher risk. Individuals with genetic predispositions, a strong family history of breast cancer, or belonging to higher-risk groups—including African American and certain Jewish populations should consult healthcare providers about earlier and more advanced screening options.
These recommendations align with guidelines from leading medical bodies, including the United States Preventive Services Task Force, the American Cancer Society, and the National Comprehensive Cancer Network, all of which support annual screening starting at age 40 to maximize survival outcomes.
Data from the National Cancer Institute highlights that breast cancer mortality in the U.S. has declined by 40% since the widespread adoption of screening in the 1980s. Women who undergo regular screening have a significantly lower risk of death compared to those who do not.
ACR and SBI also raised concerns about ACP’s limited recommendations for women with dense breast tissue, noting that additional screening methods beyond digital breast tomosynthesis (DBT) are often necessary for accurate detection.
Addressing concerns around screening risks, the organizations stated that issues such as false positives are typically resolved with follow-up imaging and have no long-term health impact. Studies show that most women who experience false positives continue to support regular screening.
“Breast cancer screening saves lives, and consistent, evidence-based guidelines are essential to ensuring the best outcomes for patients,” the organizations emphasized, urging ACP to align its recommendations with cancer experts.
